US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Bio Vitos Pharma AB (publ) appoints LAGO KAPITAL as liquidity provider

Bio Vitos Pharma AB (publ) (”Bio Vitos”) has entered into a liquidity provider agreement with Lago Kapital (”LAGO”).According to the agreement, LAGO undertakes to continuously quote prices on both the buy- and sell side for Bio Vitos share in accordance with the framework of Nasdaq Stockholm´s rules for liquidity provision. The purpose is to promote liquidity and reduce spread and volatility of the share. LAGO´s assignment commences on 15th of november 2024.  For further information, contact: Bio Vitos Pharma AB (publ) Jesper Birgemo, CEO Tel: +46 (0) 70 895 39 34 About Bio

KFUM Kalmar and Bio Vitos Pharma enter into an agreement regarding a research study on Succifer

KFUM Kalmar and Bio Vitos Pharma have signed a collaboration agreement to conduct a research study entitled "Effect of oral iron succinate on iron deposits and exercise capacity in female athletes." This agreement marks an important step forward in strengthening the scientific evidence and investigating Succifer's potential benefits for female athletes.The study will include 60 female athletes from Kalmar and will be conducted under the direction of Linnaeus University. Participants will be divided into three groups of 20 participants in each group to compare the effects of Succifer

The European Patent Office EPO grants patent that is important to Bio Vitos Pharma

The European Patent Office (EPO) has granted a patent for the treatment of heart failure patients with reduced ejection fraction, with oral iron succinate. The patent provides protection in 26 countries and Bio Vitos Pharma owns the rights to this patent within the EU excluding the Nordic countries.- This is very positive news for Bio Vitos Pharma. This enables strong protection for our iron succinate product Succifer which we are developing and increases our future revenue potential. Via Double Bond Pharmaceutical (DBP), Bio Vitos Pharma also owns the rights to other identical patent

Hemcheck completes the transaction with Bio Vitos

Hemcheck has today completed the transaction with Bio Vitos as Bio Vitos has subscribed for all the shares according to the agreement and paid in the agreed funds so that the decided new share issue can be carried out.- It is very positive that we have completed the transaction with Bio Vitos and that the company can now take the next step in line with the plan that has been drawn up. The IP rights regarding iron succinate have large potential and now the work begins to realize this potential. Shortly we will call for an extra general meeting to elect new board members and change the name

Hemcheck has received a first order from its distributor Astemed

Hemcheck has received a first smaller order from Astemed, which is the company's distributor in the United Arab Emirates. The order concerns instruments and v-Test and is of minor economic value.- It is very positive with a first order from Astemed and the United Arab Emirates. There is a very interesting potential in the regional market, and we of course hope that this is the first in a series of orders from there, says Joen Averstad, acting CEO of Hemcheck. For further information contact: Hemcheck Sweden AB (publ) Joen Averstad, acting CEO Tel: +46 76 108 8191 Email: joen.

Hemcheck submits a formal application to Nasdaq for a decision on continued listing before the implementation of the Bio Vitos agreement

Hemcheck has today submitted the formal application to Nasdaq to obtain a conditional approval for continued listing in connection with the implementation of the BioVitos agreement. The company hope to receive a decision from Nasdaq within about a month.More about the possible Transaction If the deal is completed, it will, as previously communicated, mean that Hemcheck will acquire capital and IP rights relating to the use of iron succinate for the treatment of patients diagnosed with heart failure with reduced ejection fraction (HFrEF) in the US, Europe excluding the Nordic countries,

Additional follow up order from the Foundation for Innovative New Diagnostics (FIND)

Hemcheck Sweden AB has received a new follow up order from the Foundation for Innovative New Diagnostics (FIND) regarding delivery of reader and one-time tests (v-Test). The order is worth over 10,000 EUR.-Our collaboration with FIND continues, which is very positive. We continue see good potential in the collaboration where we can help and strengthen the quality work within their large network of healthcare facilities and biobanks, says Joen Averstad, acting CEO of Hemcheck. For further information contact: Hemcheck Sweden AB (publ) Joen Averstad, acting CEO Tel: +46 76 108

Hemcheck has received a first order from the university hospital Charité in Berlin

Hemcheck has received a first small order from the university hospital Charité in Berlin. Charité is one of the largest university hospitals in Europe with a budget of approximately EUR 2.3 billion. The order concerns bgs-Test and is of lower economic value.- It is very positive with a first order from Charité. The hospital is a very large university hospital and a reference hospital for many other possible customers both in Germany and internationally. We of course hope that this can be the start of a longer collaboration with Charité, says Joen Averstad, acting CEO of Hemcheck. For

Additional agreement with Bio Vitos Medical brings forward the time for calling the extraordinary general meeting by one week

Hemcheck and Biovitos have signed an additional agreement which enables Hemcheck to send out a calling to the extra general shareholders meeting that will decide on the deal, one week later than what is stipulated in the agreement signed on February 7. The last day to send the calling is now set to March 28. The reason is purely administrative.For further information contact: Hemcheck Sweden AB (publ) Joen Averstad, acting CEO Tel: +46 76 108 8191 Email: joen.averstad@hemcheck.com About Hemcheck Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-

Hemcheck has received a first follow up order from its Finnish distributor

Hemcheck has received a first follow-up order from its Finnish distributor, Vingmed, which is also Hemcheck's distributor in Sweden and Norway. The order concerns s-Test and bgs-Test and is of minor economic value.- It is very positive with a first follow-up order from Finland, which shows the activity in the market. We look forward to our continued cooperation with Vingmed in Finland, says Joen Averstad, acting CEO of Hemcheck. For further information contact: Hemcheck Sweden AB (publ) Joen Averstad, acting CEO Tel: +46 76 108 8191 Email: joen.averstad@hemcheck.com About

Hemcheck has received an additional follow up order from its UK distributor

Hemcheck has received another follow-up order from its UK distributor, CLS. The order concerns instruments for diagnostic use and bgs-Test and is of lower economic value.- We have a good trend with several follow-up orders, which is very positive. It is still products for diagnostic use that are in highest demand and show good potential, says Joen Averstad, CEO of Hemcheck. For further information contact: Hemcheck Sweden AB (publ) Joen Averstad, CEO Tel: +46 76 108 8191 Email: joen.averstad@hemcheck.com About Hemcheck Hemcheck Sweden AB, founded in 2010, produces and

Hemcheck receives follow up order from research program in the United States

Hemcheck Sweden AB has received a follow-up order from AREVA in the US. The order is a follow-up order after a first successful evaluation phase and is for research use. AREVA is a research program of The Geneva Foundation, which is a non-profit organization focused on research, development and education in military medicine. AREVA collaborates with private players, academic institutions and with government agencies and bodies such as the US military and the FDA.- It is very positive that AREVA is satisfied and wants to continue the collaboration with Hemcheck. As communicated earlier, we

Hemcheck has received a follow up order from its French distributor

Hemcheck has received a follow-up order from its French distributor, Eurobio Scientific, corresponding to approximately SEK 80,000. The order concerns instruments for diagnostic use.- We have a positive trend in terms of sales, which is very positive. Several of our distributors are very active and there is clear potential in especially the larger markets. We hope and believe we will get more similar orders, says Joen Averstad, CEO of Hemcheck. For further information contact: Hemcheck Sweden AB (publ) Joen Averstad, CEO Tel: +46 76 108 8191 Email: joen.averstad@hemcheck.com

Hemcheck has received a follow up order from its UK distributor

Hemcheck has received a follow-up order from its UK distributor, CLS. The order concerns instruments for diagnostic use and bgs-Tests and is of smaller economic value.- Orders continue to come in, which is very positive. It is mainly products for diagnostic use that show good potential and as the British market is very large, we hope for more orders from there, says Joen Averstad, CEO of Hemcheck. For further information contact: Hemcheck Sweden AB (publ) Joen Averstad, CEO Tel: +46 76 108 8191 Email: joen.averstad@hemcheck.com About Hemcheck Hemcheck Sweden AB, founded

Hemcheck has received a first order from a leading hospital in Iceland

Hemcheck has received a first order from Landspitali, the leading university hospital in Iceland. The order is a first test order regarding both v-Test and bgs-Test and is of lower economic value.- It is very positive news that we have received this first order from Landspitali. It is a reputable hospital and we hope for more orders from them, says Joen Averstad, CEO of Hemcheck. For further information contact: Hemcheck Sweden AB (publ) Joen Averstad, CEO Tel: +46 76 108 8191 Email: joen.averstad@hemcheck.com About Hemcheck Hemcheck Sweden AB, founded in 2010, produces

Hemcheck has received a follow up order from its Spanish distributor

Hemcheck has received a follow-up order from its Spanish distributor, SDO Medical. The order concerns instruments for diagnostic use and is of minor economic value.- It is very positive that we have received this follow-up order, even if it is of a smaller size. We believe a lot in the Spanish market and hope to get more orders from there, says Joen Averstad, CEO of Hemcheck. For further information contact: Hemcheck Sweden AB (publ) Joen Averstad, CEO Tel: +46 76 108 8191 Email: joen.averstad@hemcheck.com About Cruinn Read more at https://www.cruinndiagnostics.ie/

Hemcheck has received another follow up order from its Irish distributor

Hemcheck has received another follow-up order from its Irish distributor, Cruinn Diagnostics (“Cruinn”). The order concerns one-time tests for both vacuum tubes and syringes.- We continue to receive orders from Cruinn in Ireland, with whom we have a good cooperation. The orders are of a smaller size, but it is a good sign based on the evaluations that Cruinn is now performing with customers. We look forward to their continued sales work, says Joen Averstad, CEO of Hemcheck. For further information contact: Hemcheck Sweden AB (publ) Joen Averstad, CEO Tel: +46 76 108 8191

Hemcheck extends agreement regarding previously communicated project with Region Skåne

Hemcheck has extended the agreement with Laboratory Medicine within Region Skåne, Sweden. The extension involves minor revenues for Hemcheck and is related to the same project as previously communicated where Hemcheck's v-Test with equipment configured for diagnostic use is used.- We continue to view this project very positively and hope it can be an important step towards a potential larger collaboration with the region after the project is completed, which will most likely happen in the second quarter of this year, says Joen Averstad, CEO of Hemcheck. For further information contact:

Hemcheck has received a follow up order from its Irish distributor

Hemcheck has received another follow-up order from its Irish distributor, Cruinn Diagnostics (“Cruinn”). The order concerns instruments for diagnostic use and is linked to a university hospital that evaluates the products.- It is very positive that we received this follow-up order. We have a good collaboration with Cruinn and if the evaluation that will take place has a positive outcome, there are good chances for additional and larger orders from them, says Joen Averstad, CEO of Hemcheck. For further information contact: Hemcheck Sweden AB (publ) Joen Averstad, CEO Tel: +46 76

Hemcheck has received an important order from a major OEM

Hemcheck has received an important order from a major OEM worth over SEK 120,000. The order concerns several systems for hemolysis detection and single-use tests for diagnostic use and is carried out to evaluate Hemcheck's technology.- Its very positive that we have received this order as we want to start more collaborations and do business with other larger companies. Hopefully they can get started quickly with the evaluation and that this will lead to further commercial or structural opportunities for us in the first quarter of next year, says Joen Averstad, CEO of Hemcheck. For

Hemcheck has received an important follow up order from Deutsches Herzzentrum Berlin

Hemcheck has received an important follow-up order from Deutsches Herzzentrum Berlin worth approximately SEK 150,000. The order concerns several systems for hemolysis detection for diagnostic use and is made after a successful evaluation period since the summer.- We are continuing the good trend especially in the diagnostic area, which is very good news. Deutsches Herzzentrum Berlin is an important reference customer, and we hope that this can lead to that more customers will implement our products, especially in Germany which is an important market, says Joen Averstad, CEO of Hemcheck.

Hemcheck receives additional follow up order from its Greek distributor

Hemcheck Sweden AB has received an additional follow-up order from its Greek distributor Antisel. The order is of lower economic value, but shows again that Antisel is active in the market and that Greek customers demand Hemcheck's products.- We are happy about the interest in Hemcheck's products, not only in Greece but in several other markets where we have good momentum, and we of course hope that this order will be followed by more and bigger orders, says Joen Averstad, CEO of Hemcheck. For further information contact: Hemcheck Sweden AB (publ) Joen Averstad, CEO Tel: +46 76

Hemcheck receives follow up order from its Italian distributor

Hemcheck Sweden AB has received a small follow-up order from Levi Biotech, its Italian distributor. The order is in addition to the initial order already placed in connection with the signing of the agreement with Levi Biotech.- It is clearly positive that we received this follow-up order as it shows the interest and need that exists. We have several ongoing product evaluations with possible customers in Italy and we hope to get addtional repeat orders, says Joen Averstad, CEO of Hemcheck. For further information contact: Hemcheck Sweden AB (publ) Joen Averstad, CEO Tel: +46 76

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe